Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support... see more

Recent & Breaking News (NDAQ:AUPH)

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Business Wire 9 days ago

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Business Wire 13 days ago

Aurinia to Participate in Jefferies London Healthcare Conference

Business Wire November 14, 2024

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

Business Wire November 7, 2024

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

Business Wire November 7, 2024

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024

Business Wire October 30, 2024

Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis

Business Wire September 24, 2024

Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference

Business Wire September 13, 2024

Aurinia Announces Board Restructuring

Business Wire September 12, 2024

Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial

Business Wire September 5, 2024

Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Business Wire August 28, 2024

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results

Business Wire August 1, 2024

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024

Business Wire July 19, 2024

Aurinia to Participate in Upcoming Investor Healthcare Conferences

Business Wire July 2, 2024

Aurinia Announces 2024 Annual General Meeting Results

Business Wire June 14, 2024

Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024

Business Wire June 5, 2024

Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce

Business Wire June 4, 2024

Aurinia Provides Update on Proxy Statement

Business Wire June 3, 2024

Aurinia Will Attend 2024 Jefferies Global Healthcare Conference

Business Wire May 30, 2024

Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024

Business Wire May 14, 2024